AbbVie (ABBV): Life After Humira is Better Than Expected
At ~$200, AbbVie has navigated the Humira patent cliff more successfully than most predicted. Skyrizi and Rinvoq are delivering, and the framework reads markup.
Company Overview
AbbVie generates approximately $56 billion in annual revenue across immunology, oncology, neuroscience, and aesthetics. Humira was the best-selling drug in pharmaceutical history, peaking at $21 billion in annual sales. The biosimilar onslaught began in 2023, and Humira revenue has declined precipitously since.
But AbbVie prepared. Skyrizi (IL-23 inhibitor) and Rinvoq (JAK inhibitor) are growing rapidly, with combined annual revenue approaching $20 billion and on track to exceed Humira’s peak within a few years. These are genuinely better medicines in many indications, which is why the transition from Humira has been less destructive than feared.
The aesthetics business (Botox, Juvederm, CoolSculpting from the Allergan acquisition) adds diversification outside traditional pharma. Neuroscience assets, including treatments for migraine, Parkinson’s, and Alzheimer’s, represent the next growth frontier.
Framework Read: Markup Regime
The framework reads AbbVie in a markup regime. The worst of the Humira erosion has passed, and the growth assets are now driving net revenue growth. Institutional positioning reflects confidence in the post-Humira earnings trajectory.
The Transition Premium
AbbVie’s markup regime signals that the market is beginning to re-rate the company for its growth assets rather than penalising it for the Humira decline. The crossover point, where Skyrizi and Rinvoq growth exceeds Humira erosion, was the key inflection. That inflection has occurred.
The framework detects broad institutional buying consistent with a “re-basing” thesis: AbbVie’s forward earnings growth rate is now comparable to growth pharma peers, but the stock still carries a defensive pharma valuation and a generous dividend yield. That mismatch is what the markup is resolving.
Ethical Screening
AbbVie scores 70.5 on our ethical screening framework:
- Drug pricing: Humira’s pricing history attracts criticism, particularly the patent thicket strategy that delayed biosimilar competition. While legal, this is an ethical screening consideration.
- Healthcare access: Patient assistance programmes are substantial. AbbVie’s programmes provided access to medicines for millions of uninsured patients.
- R&D investment: Significant R&D spend ($7 billion+) focused on genuine medical innovation in autoimmune disease, oncology, and neuroscience.
- Governance: Clean governance structure. The Allergan acquisition integration was executed well operationally. Board composition is appropriate.
The 70.5 score is a pass. The Humira pricing and patent strategy controversies weigh on the score but do not push it below the threshold. The forward-looking portfolio is less ethically controversial than the historical Humira practices.
Valuation Context
At ~$200, AbbVie trades at approximately 15x forward earnings, in line with large-cap pharma peers. The dividend yield at 3.5% is attractive and well-covered.
Key Valuation Metrics
Forward P/E: ~15x | EV/EBITDA: ~12x | FCF Yield: ~6% | Dividend Yield: ~3.5%
AbbVie has increased its dividend for 52 consecutive years (including the pre-spinoff Abbott history). The payout ratio is manageable, and the company generates over $20 billion in free cash flow annually. This is a reliable income compounder with growth optionality from Skyrizi, Rinvoq, and the neuroscience pipeline.
What to Watch
- Skyrizi and Rinvoq combined trajectory: The $27 billion+ combined revenue target by 2027 is the cornerstone of the investment thesis. Track quarterly updates closely.
- Humira erosion stabilisation: At some point, Humira revenue stabilises at a much lower base. That stabilisation removes the largest negative drag on total revenue growth.
- Neuroscience pipeline readouts: Potential catalysts in Alzheimer’s, Parkinson’s, and psychiatric disorders could add meaningful growth vectors.
- IRA pricing negotiation impact: Several AbbVie drugs may face Medicare price negotiations. The financial impact needs to be quantified.
- Regime monitoring: Track on the ABBV ticker page. Sustained markup confirms the post-Humira re-rating thesis.
Track ABBV regime changes, ethical scores, and multi-factor convergence signals in real time.
Disclaimer: This case study is for informational and educational purposes only. It does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. All data is sourced from publicly available information and our proprietary analytical framework. Past performance and current framework readings do not guarantee future results. Always conduct your own due diligence and consult a qualified financial adviser before making investment decisions. Titan Protect is not a registered investment adviser.